Cover Story
Conversation with The Cancer LetterRegulatory News
FDA is preparing to review an estimated 25 applications for cancer drugs that are being developed based largely—and in many cases entirely—on data from mainland China.
In Brief
Clinical Roundup
Drugs & Targets
NCI Trials
NCI Trials for February 2022
The National Cancer Institute approved the following clinical research study last month.
